



Ifirmasta

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0025/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO	30/06/2021		SmPC, Labelling and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>				
IB/0024	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	21/06/2021		Annex II	
IAIN/0023	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	22/04/2021		Annex II	
A31/0018	The European Commission triggered a referral under Article 31 of Directive 2001/83/EC and requested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinal products and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked.	12/11/2020	19/02/2021	Annex II	Please refer to the assessment report: Ifirmasta EMEA/H/A-31/1471/C/962/0018

	<p>During the CHMP plenary meeting in September 2018, the scope of the referral has been widened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan). The CHMP Opinion was issued on 31 January 2019 and the Commission Decision was issued on 15 April 2019. In a letter dated 29 July 2020, the European Commission requested the EMA to assess the impact of the outcome of the Article 5(3) assessment on nitrosamines adopted on 25 June 2020 on the CHMP's opinion of 31 January 2019 for the scientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471). The CHMP was requested to give its recommendation whether the conditions of the Marketing Authorisations should be varied.</p>				
IAIN/0022/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p>	16/02/2021		Annex II and PL	
IA/0021/G	<p>This was an application for a group of variations.</p>	31/07/2020	n/a		

	<p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>				
IB/0020	B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue	07/11/2019	19/10/2020	Annex II	
IB/0019	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	10/10/2018	15/04/2019	SmPC, Labelling and PL	

IB/0017	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	05/10/2018	15/04/2019	SmPC	
IA/0016/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	21/03/2018	n/a		
IB/0015	B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	09/11/2016	n/a		
IB/0014	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	05/10/2016	14/09/2017	SmPC, Annex II, Labelling and PL	

IB/0013	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	05/12/2014	10/12/2015	SmPC, Labelling and PL	
A31/0010	On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit-risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.	22/05/2014	04/09/2014	SmPC and PL	
IA/0012	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	11/02/2014	n/a		
IA/0011	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold	20/09/2013	n/a		

	compared to the originally approved batch size				
R/0009	Renewal of the marketing authorisation.	27/06/2013	26/08/2013	SmPC, Annex II, Labelling and PL	<p>Based on the CHMP review of data on quality, safety and efficacy, including all variations introduced since the granting of the initial marketing authorisation, the CHMP considered that the benefit-risk balance of Ifirmasta in the authorised indications remains favourable and therefore recommended the renewal of the marketing authorisation, subject to the conditions as laid down in Annex II to the Opinion.</p> <p>The CHMP considered that the Marketing Authorisation could be granted with unlimited validity.</p> <p>The CHMP recommended amendments to the Annexes I, II, IIIA and IIIB. These changes do not affect the benefit-risk balance of the product, which remains positive.</p>
IAIN/0008/G	<p>This was an application for a group of variations.</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p>	19/09/2012	31/10/2012	SmPC, Labelling and PL	

	tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes				
IB/0007	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	18/05/2012	n/a		
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/03/2012	31/10/2012	PL	
IB/0005	B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF	18/07/2011	n/a		
IB/0004	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	28/01/2011	n/a	SmPC and PL	
II/0003/G	This was an application for a group of variations. to introduce changes in the manufacturing process in	16/12/2010	04/01/2011		

	<p>the synthesis of irbesartan hydrochloride active substance and to add a contract manufacturer for the synthesis of irbesartan hydrochloride active substance.</p> <p>B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p>				
IB/0002	IB_02_Change in the name of the medicinal product	24/09/2009	n/a	SmPC, Annex II, Labelling and PL	
II/0001	<p>The MAH applied for an update of the SPC sections 4.3 and 4.6 as well as PL section 2 to implement the CHMP recommendation on a harmonised labelling relating to the use of Angiotensin II Receptor Antagonists (AIIRAs) during pregnancy and lactation. Furthermore, minor typographical changes have been introduced to SPC section 4.4. In addition, the MAH took the opportunity to update PL sections 1-4 in order to align the information with the approved wording of the reference product. Moreover, the list of local representatives in the PL has been amended.</p> <p>Update of Summary of Product Characteristics and Package Leaflet</p>	23/07/2009	28/08/2009	SmPC and PL	<p>Available data regarding use of AIIRAs during lactation have been assessed. There are no concrete data to support the contraindication of use of AIIRAs during breast-feeding. All AIIRA agents were found in the milk of lactating rats but no human data about their transfer into breast milk are available. There is only a theoretical presumption of low transport according to their high plasma protein binding and low oral availability. A harmonised wording recommending an alternative treatment with better established safety profiles during breast-feeding, especially while nursing a newborn or preterm infant, has been included in section 4.6 of the SPC and Section 2 of the PL. Consequently, the existing contraindication for lactation has</p>

					been deleted.
--	--	--	--	--	---------------